Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The study results demonstrate clear separation in clinical response between the D-MNA treatment arm (73%) and P-MNA treatment arm (38%) in the 200-µg cohort at Day 57

  60% confidence

• SkinJect and Gorlin Syndrome collectively represent an approximately $2 billion market opportunity

  60% confidence

• 73% clinical clearance in the 200-µg arm suggests that approximately 3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention

  60% confidence

• Basal cell carcinoma is the most common cancer worldwide

  60% confidence

• The 200-µg treatment cohort demonstrated the strongest efficacy signal, achieving 73% clinical clearance and 40% histological clearance at Day 57

  60% confidence

• The Company believes the dataset represents decision-grade evidence supporting continued development of the SkinJect program and advancement toward regulatory discussions and potential strategic partnerships

  60% confidence

• The biological activity observed in the device-only arm likely reflects tumor disruption and localized immune activation resulting from microneedle insertion

  60% confidence

• Teverelix represents an approximately $6 billion market opportunity for cardiovascular high-risk advanced prostate cancer and acute urinary retention relapse

  60% confidence

• The magnitude of response observed in the active treatment cohort relative to the device-only control arm provides clinically meaningful evidence of drug-mediated therapeutic effect

  60% confidence